Responding to post https://hotcopper.com.au/posts/74173206/single
(Broken button - so clunky!)
What are commonly called 'phase trials' do not need to be repeated. What is required is in vivo bioequivalence studies to show that the different form of the drug is equivalent to the previously approved version (i.e.: uptake, metabolisation, etc.). This is nowhere near as taxing or time consuming as the phase trial process leading to approval to use and market the drug,
Bioequivalence can be more challenging to achieve when moving from intrathecal administration to IV administration (due to the blood-brain barrier), or from IV administration to oral administration. Moving from solid to liquid via the same administration pathway is unlikely to pose difficulties - in fact (depending on whether the 'liquid' is a solution or a suspension) it may well be taken up more readily in liquid form requiring a retitration to lower the amount of API needed to achieve the same concentration in the blood.
Cheers
Densy
- Forums
- ASX - By Stock
- PAA
- Pipeline-in-a-drug
Pipeline-in-a-drug, page-20
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
17.5¢ |
Change
-0.020(10.3%) |
Mkt cap ! $85.08M |
Open | High | Low | Value | Volume |
19.0¢ | 19.0¢ | 17.5¢ | $245.7K | 1.349M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 347692 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 35481 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 347692 | 0.175 |
3 | 204303 | 0.170 |
4 | 19700 | 0.165 |
3 | 18451 | 0.150 |
1 | 3600 | 0.140 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 35481 | 1 |
0.185 | 50000 | 1 |
0.190 | 296982 | 6 |
0.195 | 137119 | 6 |
0.200 | 373778 | 11 |
Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |